MIGLIETTA, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.187
EU - Europa 275
AS - Asia 178
SA - Sud America 4
Totale 2.644
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.186
IT - Italia 128
CN - Cina 117
FI - Finlandia 51
SE - Svezia 38
HK - Hong Kong 23
GB - Regno Unito 22
IN - India 18
DE - Germania 17
VN - Vietnam 11
IE - Irlanda 8
BR - Brasile 4
PH - Filippine 4
BE - Belgio 3
ES - Italia 2
FR - Francia 2
JP - Giappone 2
AL - Albania 1
CA - Canada 1
CH - Svizzera 1
HR - Croazia 1
IR - Iran 1
KR - Corea 1
KZ - Kazakistan 1
NL - Olanda 1
Totale 2.644
Salva come PNG Salva come JPEG
Città #
Fairfield 379
Chandler 281
Ashburn 197
Woodbridge 183
Houston 164
Cambridge 146
Seattle 139
Ann Arbor 126
Wilmington 111
Padova 45
Helsinki 43
San Diego 37
Beijing 36
Medford 35
Princeton 35
Des Moines 27
Roxbury 27
Boardman 16
London 12
New York 12
Dong Ket 11
Jinan 11
Nanjing 11
Milan 10
Pune 10
Codogno 9
Dublin 8
Zhengzhou 8
Norwalk 7
Falls Church 6
Washington 6
Shenyang 5
Lappeenranta 4
Rome 4
Brussels 3
Changsha 3
Chiswick 3
Guangzhou 3
Hamburg 3
Nanchang 3
Redwood City 3
Selvazzano Dentro 3
Tianjin 3
Venice 3
Andrano 2
Avezzano 2
Bergamo 2
Capo d'Orlando 2
Clermont-Ferrand 2
Council Bluffs 2
Haikou 2
Hefei 2
Hong Kong 2
Hounslow 2
Lanzhou 2
Los Angeles 2
Mabalacat 2
New Bedfont 2
Pasig 2
Perugia 2
Sale Marasino 2
Selargius 2
Sestu 2
Turin 2
Vimercate 2
Almaty 1
Apiro 1
Barcelona 1
Costabissara 1
Decatur 1
Dongguan 1
Enschede 1
Falkenstein 1
Gunzenhausen 1
Iesi 1
Kilburn 1
Marana 1
Marche 1
Miami 1
Ningbo 1
Ogden 1
Prescot 1
Rockville 1
Seoul 1
Simi Valley 1
São Paulo 1
Tehran 1
Tirana 1
Tokyo 1
Toronto 1
Vicenza 1
Zagreb 1
Zurich 1
Totale 2.261
Salva come PNG Salva come JPEG
Nome #
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 171
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 136
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 133
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 127
Immune characterization of breast cancer metastases: Prognostic implications 120
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 119
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 119
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 116
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 114
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 113
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 91
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 91
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 87
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives 85
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 75
Abdominal Wall Reconstruction: Biomaterialsand Tissue Engineering Biomaterials 70
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 61
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 57
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 54
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 54
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 53
Evolution of HER2-low expression from primary to recurrent breast cancer 53
Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer: A review of the current literature 51
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 46
Complicanze tromboemboliche in chirurgia plastica: osservazioni su 20000 procedure di chirurgia maggiore 42
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 42
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review 36
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 35
Olaparib for advanced breast cancer 33
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 32
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 30
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 28
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 28
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 26
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 23
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications 22
HER2: a never ending story 20
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 19
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 18
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 18
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 16
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 13
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 13
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 10
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 9
An overview of immune checkpoint inhibitors in breast cancer 9
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 9
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 7
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 7
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 6
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 5
How can we refine the prognostic stratification of triple-negative breast cancer? 2
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 1
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 1
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 1
Totale 2.757
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.574
article - articoli 12.334
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 139
Totale 25.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201981 0 0 0 0 0 0 0 0 0 17 34 30
2019/2020540 23 5 19 132 48 26 53 56 69 59 34 16
2020/2021590 14 33 28 24 16 113 45 49 72 107 48 41
2021/2022562 23 48 55 27 64 33 68 34 39 17 39 115
2022/2023556 93 70 35 68 54 59 20 28 88 3 30 8
2023/2024345 44 48 50 27 32 59 35 16 7 27 0 0
Totale 2.757